Enlivex Therapeutics Ltd. ENLV · Stock Open Enlivex Therapeutics Ltd. in new tab
Enlivex Therapeutics Ltd. Analysis (ENLV)
Is Enlivex Therapeutics Ltd. a good investment? Enlivex Therapeutics Ltd. (ENLV) is currently trading at 0.4227 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Enlivex Therapeutics Ltd. is undervalued compared to historical market norms.
Earnings Schedule: Enlivex Therapeutics Ltd. is expected to release its next earnings report on Dec. 7, 2026. The market consensus estimate for Forward EPS is -0.78.
Investor FAQ
Does Enlivex Therapeutics Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Enlivex Therapeutics Ltd.?
Enlivex Therapeutics Ltd. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Dec. 7, 2026. The company currently has a trailing EPS of 1911.77.
Company Profile
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 25, 2017 | 1:5 |
| March 6, 2019 | 1:8 |
| July 9, 2026 | Needs review |
Community Discussion